Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
295 participants
OBSERVATIONAL
2016-09-13
2020-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Childhood Obesity Microbiome Study
NCT04770311
Composition and Collection Feasibility of Gut Microbiota in Children With and Without Obesity
NCT03149601
Mechanisms of Obesity and Its Metabolic Complications in Youth
NCT03454828
Response of the Gut Microbiome and Circulating Metabolome to Diet in Children: Ancillary Study to KIDFIT (NCT03405246)
NCT03612479
Gut Microbiota Composition in Hispanic and Non-Hispanic Children.
NCT03990350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Comparison Cohort: two comparison groups be enrolled:(1c) healthy siblings of enrolled intervention subjects and (2c) age/sex matched controls recruited from the Duke Children's Primary Care Clinic.
Up to 350 participants will be enrolled, with the goal of 295 evaluable participant data. The study period is six months for all groups with the exception of the bariatric surgery group which will last from baseline until after surgery, up to 12 months. The comparison groups will have one visit at baseline only.
Stool Sample Collection: Participants in both intervention and comparison groups will provide a fecal sample at enrollment or within 3 days of enrollment. Participants in intervention groups (Groups 1-4) will provide additional fecal samples at 1.5, 3, 4.5, and 6 months. Given that the ability to collect fecal samples is unpredictable, the investigator will develop a standard operating procedure along the following guidelines:
1. At the first visit, if the subject cannot provide a sample at the time of enrollment, the investigator will give the participant/parent a cooler/ice pack and sample collection kit. The investigator will ask the subject to provide the "baseline" sample within 3 days of the first visit. The sample will be refrigerated for up to 24 hours prior to pick up by the clinical research staff or delivery by the parent/guardian, with compensation for miles. With pick up or delivery a new cooler and freezer pack as well as sample collection kit will be provided for the following sample collection.
2. Within a 2-week window, centered on collection points 1.5 and 4.5 months, the subjects will provide additional samples. They may either have the samples picked up within 24 hours of collection (with refrigeration from collection to pick up) or get reimbursed for mileage.
3. For the 3-month and 6-month collections, which occur in conjunction with a regularly scheduled Healthy Lifestyles visit, the patients will collect a sample within 24 hours prior to the visit and bring with them to clinic. At the 3-month visit they will be sent home with new collection kits, freezer packs, and coolers.
4. If a patient cannot provide a sample within 24 hours of a clinic visit or a sample is missed, we will still collect a sample as soon as the patient is able to provide it and arrange for pickup or delivery as outlined below, noting the sample as "out of window."
Plasma sample collection: Participants in intervention groups will provide a 20mL blood samples at baseline, 3 and 6 months at the time of a regular HLP visit. The standard HLP clinical protocol is to draw fasting labs at baseline and 6 months, so no additional blood draws beyond what is required for clinical care will be required at those visits. However, HLP patients do not typically have a blood draw at 3 months, so participants will be asked for a blood sample at 3 months they would not otherwise require. Participants in comparison groups (Groups 1c, 2c) will be asked for a blood sample at enrollment only; they would not otherwise require this sample.
Analysis of samples: Fecal samples will be analyzed for the composition of the microbiota using DNA sequencing methods. Specific bacteria associated with obesity will be isolated from fecal samples and studied in the laboratory for their metabolism. A subset of fecal samples will be transferred into the intestinal tracts of germ free mice to study the effects on their metabolism. Participant plasma will be analyzed for panels of metabolites that are associated with diabetes mellitus and obesity. Blood mononuclear cell DNA will be used for focused genetic testing to identify genetic changes associated with obesity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HLP
Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.
Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.
Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference.
No interventions assigned to this group
Healthy Weight Siblings
Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
No interventions assigned to this group
Healthy Weight age/sex matched controls
Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.
This group will be asked to provide a fecal and blood sample at one time point.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sexual Maturity Rating 2 or above (pubertal)
* Age- and gender-specific BMI ≥ 95th percentile
* Expected enrollment in Healthy Lifestyles Clinical Program \> 6 months
Exclusion Criteria
* Anticipated antibiotic use during the course of the study.
* Immunodeficiency or prior transplantation
* Type 1 diabetes mellitus
* Inborn error of metabolism
* No fluency in English or Spanish
* Identifiable cause of obesity including hypothyroidism, Cushing syndrome, known genetic obesity syndrome including melanocortin receptor 4 mutation, drug-induced obesity including steroids or anti-psychotics
* Significant medical or mental health condition that precludes treatment
* Receiving insulin
* Plans to move away from area in next 6 months
* Weight loss of \>5% total body weight in prior 3 months
* Pregnancy (self-report, confirm with noted last menstrual period in chart)
* Home outside of a 50 mile radius from the HL Clinic.
10 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah C Armstrong, MD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Health System
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McCann JR, Yang C, Bihlmeyer NA, Tang R, Truong T, An J, Jawahar J, Ilkayeva O, Muehlbauer MJ, Hu Z, Dressman HK, Poppe L, Granek JA, David LA, Shi P, Balikcioglu PG, Shah SH, Armstrong SC, Newgard CB, Seed PC, Rawls JF. Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy. medRxiv [Preprint]. 2025 Jun 9:2025.02.03.25321363. doi: 10.1101/2025.02.03.25321363.
Suarez L, Skinner AC, Truong T, McCann JR, Rawls JF, Seed PC, Armstrong SC. Advanced Obesity Treatment Selection among Adolescents in a Pediatric Weight Management Program. Child Obes. 2022 Jun;18(4):237-245. doi: 10.1089/chi.2021.0190. Epub 2021 Nov 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00074729
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.